These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 6154898)

  • 1. Phase I study using combination of hydroxyurea and 5-azacytidine (NSC-102816).
    Lomen PL; Khilanani P; Kessel D
    Neoplasma; 1980; 27(1):101-6. PubMed ID: 6154898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of refractory adult acute nonlymphoblastic leukemia with subcutaneous 5-azacytidine.
    Armitage JO; Burns CP
    Cancer Treat Rep; 1977 Dec; 61(9):1721-3. PubMed ID: 74285
    [No Abstract]   [Full Text] [Related]  

  • 3. Combination therapy with 5-azacytidine plus beta-2'-deoxythioguanosine in adult acute leukemia.
    Omura GA
    Cancer Treat Rep; 1977 Aug; 61(5):915-7. PubMed ID: 70273
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II study of 5-azacytidine in solid tumors.
    Weiss AJ; Metter GE; Nealon TF; Keanan JP; Ramirez G; Swaiminathan A; Fletcher WS; Moss SE; Manthei RW
    Cancer Treat Rep; 1977; 61(1):55-8. PubMed ID: 67894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of pyrazofurin and 5-azacytidine in refractory adult acute leukemia.
    Martelo OJ; Broun GO; Petruska PJ
    Cancer Treat Rep; 1981; 65(3-4):237-9. PubMed ID: 6165467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clinical trial of pyrazofurin in combination with 5-azacytidine in acute adult nonlymphocytic leukemia.
    Van Echo DA; Chiuten DF; Markus S; Wiernik PH
    Cancer Clin Trials; 1981; 4(2):129-33. PubMed ID: 6166406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-azactidine and zorubicin for patients with previously treated acute nonlymphocytic leukemia: a Cancer and Leukemia Group B pilot study.
    Peterson BA; Bloomfield CD; Gottlieb AJ; Coleman M; Greenberg MS
    Cancer Treat Rep; 1982 Mar; 66(3):563-6. PubMed ID: 6174230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with 5-azacytidine (NSC-102816) and methyl-GAG (NSC-32946) in previously treated adults with acute nonlymphocytic leukemia.
    Levi JA; Wiernik PH
    Cancer Chemother Rep; 1975; 59(5):1043-5. PubMed ID: 54215
    [No Abstract]   [Full Text] [Related]  

  • 9. Pilot study of 5-azacytidine (5-AZA) and carboplatin (CBDCA) in patients with relapsed/refractory leukemia.
    Kritz AD; Raptis G; Menendez-Botet C; Maslak P; Jakubowski A
    Am J Hematol; 1996 Feb; 51(2):117-21. PubMed ID: 8579051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
    Samuels BL; Herndon JE; Harmon DC; Carey R; Aisner J; Corson JM; Suzuki Y; Green MR; Vogelzang NJ
    Cancer; 1998 Apr; 82(8):1578-84. PubMed ID: 9554537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twice weekly 5-azacytidine infusion in dissmeinated metastatic cancer: a phase II study.
    Vélez-Garcia E; Vogler WR; Bartolucci AA; Arkun SN
    Cancer Treat Rep; 1977 Dec; 61(9):1675-7. PubMed ID: 74283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
    Kaminskas E; Farrell AT; Wang YC; Sridhara R; Pazdur R
    Oncologist; 2005 Mar; 10(3):176-82. PubMed ID: 15793220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of 5-azacytidine (NSC-102816).
    Shnider BI; Baig M; Colsky J
    J Clin Pharmacol; 1976 Apr; 16(4):205-12. PubMed ID: 57124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive chemotherapy with daunorubicin, 5-azacytidine, 6-thioguanine, and cytarabine (DATA) for the blastic transformation of chronic granulocytic leukemia.
    Winton EF; Miller D; Vogler WR
    Cancer Treat Rep; 1981; 65(5-6):389-92. PubMed ID: 6165470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective remission induction of refractory childhood acute nonlymphocytic leukemia by VP-16-213 plus azacitidine.
    Look AT; Dahl GV; Kalwinsky D; Senzer N; Mason C; Rivera G
    Cancer Treat Rep; 1981; 65(11-12):995-9. PubMed ID: 6170431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of subcutaneously administered 5-azacytidine (NSC-102816) in patients with metastatic malignant melanoma.
    Bellet RE; Catalano RB; Mastrangelo MJ; Berd D
    Med Pediatr Oncol; 1978; 4(1):11-5. PubMed ID: 75498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
    Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
    Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxyurea toxicity combined with didanosine (ddl) in HIV-1-seropositive asymptomatic individuals.
    Seminari E; Lisziewicz J; Tinelli C; Foli A; Lori F; Maserati R
    Int J Clin Pharmacol Ther; 1999 Oct; 37(10):514-8. PubMed ID: 10543320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of twice weekly 5-azacytidine (NSC-102816).
    Vogler WR; Arkun S; Velez-Garcia E
    Cancer Chemother Rep; 1974; 58(6):895-9. PubMed ID: 4141280
    [No Abstract]   [Full Text] [Related]  

  • 20. Hydroxyurea and didanosine is a more potent combination than hydroxyurea and zidovudine.
    Foli A; Lori F; Maserati R; Tinelli C; Minoli L; Lisziewicz J
    Antivir Ther; 1997 Jan; 2(1):31-8. PubMed ID: 11322264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.